POULVAC LARYNGO SA2

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

Buy It Now

Active ingredient:
INFECTIOUS LARYNGOTRACHEITIS VIRUS STRAIN S.A.2; GENTAMICIN; NYSTATIN
Available from:
ZOETIS AUSTRALIA PTY LTD
INN (International Name):
vaccine - ILT
Pharmaceutical form:
MISC. VACCINES OR ANTI SERA
Composition:
INFECTIOUS LARYNGOTRACHEITIS VIRUS STRAIN S.A.2 VACCINE-VIRAL Active 0.0 P; GENTAMICIN ANTIBIOTIC Other 0.44 ug/do; NYSTATIN ANTIBIOTIC Other 0.44 units/do
Units in package:
!10 x 500; !Dose vial; #10 x 2000; #Dose vial; %10 x 750; %doses; *10 x 1000; *Dose vial; ^10 x 1500; ^doses; 1000 Doses; 2000 D
Class:
VM - Veterinary Medicine
Manufactured by:
ZOETIS AUSTRALIA
Therapeutic group:
POULTRY | BREEDERS | BROILER | CHICKENS | CHICKS | CHOOKS | DAY OLD CHICKS | HATCHLINGS | LAYERS
Therapeutic area:
IMMUNOTHERAPY
Therapeutic indications:
INFECTIOUS LARYNGOTRACHEITIS | GALLID HERPESVIRUS 1 | ILT
Product summary:
Poison schedule: 0; Withholding period: WHP:NIL; Host/pest details: POULTRY: [INFECTIOUS LARYNGOTRACHEITIS]; Poison schedule: 0; Withholding period: ; Host/pest details: POULTRY: [INFECTIOUS LARYNGOTRACHEITIS]; For the prevention of infectious laryngotracheitis in poultry.See WARNING STATEMENT on ILTV vaccine viruses.
Authorization status:
Registered
Authorization number:
50573
Authorization date:
2019-07-01

Company Name:

Product Name:

Product No:

ZOETIS AUSTRALIA PTY LTD

POULVAC LARYNGO SA2

50573/101106

Label Name:

POULVAC LARYNGO SA2

Signal Headings:

FOR ANIMAL TREATMENT ONLY

Constituent

Statements:

Infectious laryngotracheitis virus (SA2 strain;

10^4.1pfu)

Gentamicin (0.44 µg ) and Nystatin (0.44 units) added as preservatives.

Claims:

For the prevention of infectious laryngotracheitis in poultry

Net Contents:

10 x 500 doses

10 x 750 doses

10 x 1000 doses

10 x 1500 doses

10 x 2000 doses

Directions for Use:

Before Reconstitution

The vaccine will remain potent until the expiry date if stored below –5°C (freeze).

Reconstituted Vaccine

Once reconstituted, the vaccine must be used immediately.

Special precautions should be taken to avoid heat and light damage to the vaccine during

use.

If ambient temperatures are expected to be high, small volumes of vaccine should be

reconstituted and used quickly.

Covered insulated containers containing ice should be used for the movement of vaccine

vials from the main storage area to areas of use around the farm.

Restraints:

Contraindications:

Precautions:

1. Simultaneous administration of Poulvac Laryngo SA2 and Infectious Bronchitis vaccines

is not recommended.

RLP

APPROVED

For Official Use Only

2. Only birds in good health should be vaccinated. The presence of either concurrent

infections (e.g. mycoplasmosis, coryza) or husbandry stress factors may cause a reaction.

3. The use of disinfectants or antiseptics in or on any equipment used for the preparation of

Poulvac Laryngo SA2 must be avoided.

4. Sanitising chemicals in the farm water supply should not be used for 3 days prior to

vaccination with Poulvac Laryngo SA2.

5. All recommendations on the storage and care of the unreconstituted vaccine must be

followed.

6. Reconstituted vaccine must be prepared, stored and transported as recommended. It

must be used immediately after reconstitution.

7. ALL BIRDS MUST RECEIVE THE FULL DOSE OF LIVING VACCINE TO BE FULLY

PROTECTED.

Please note that management conditions must be satisfactory if vaccination with Poulvac

Laryngo SA2 by drinking water method is to be successful.

Side Effects:

Dosage and

Administration:

When to vaccinate

Birds are normally vaccinated at 7-10 days and at 8-12 weeks of age.

In normal commercial poultry flocks, the two vaccination programs are considered to

provide lifelong immunity.

In isolated flocks, protection lasts only 16-20 weeks.

Two methods of administration are recommended, eye drop and drinking water.

1. Eye Drop

Reconstitution:

Reconstitute the vaccine with Poulvac® Eyedrop Diluent. Poulvac® Eyedrop Diluent is

supplied in a plastic bottle which becomes the dropper bottle when the provided dropper

cap is fitted.

To reconstitute:

500 Dose Vaccine; The diluent (approximately 30 mL per bottle) is added to the virus

in two vials of vaccine, and after shaking the contents of both are poured into the diluent

bottle and the dropper cap fitted.

750 Dose Vaccine; Withdraw 7.5 mL of diluent (containing approximately 30 mL per

bottle) and discard. Add the remaining diluent from the bottle to the virus in one vial of

vaccine. After shaking the contents are poured into the diluent bottle and the dropper cap

fitted.

1000 Dose Vaccine; The diluent (approximately 30 mL per bottle) is added to the virus in

one vial of vaccine, and after shaking the contents are poured into the diluent bottle and the

dropper cap fitted.

1500 Dose Vaccine; Withdraw 7.5 mL of diluent (containing approximately 30 mL per

bottle) from each of two diluent bottles (total of 15 mL) and discard. Withdraw 1 mL of the

remaining diluent from each bottle (total of 2 mL). Add to the virus in one vial of vaccine

and after shaking draw up the total volume of reconstituted vaccine virus into a syringe.

Determine the total volume from graduations on the syringe and deliver half of this amount

to each of the two diluent bottles and fit a dropper cap to each.

2000 Dose Vaccine; Withdraw 1 mL of diluent (approximately 30 mL per bottle) from

each of two diluent bottles (total of 2 mL). Add the 2 mL of diluent to the virus in the vial,

and after shaking draw up the total volume of reconstituted vaccine virus into a syringe.

Determine the total volume from graduations on the syringe and deliver half of this amount

to each of the two diluent bottles and fit a dropper cap to each.

If ambient temperatures are expected to be high, one vial of vaccine at a time should be

reconstituted and used immediately.

Administration:

Hold the bird with the eye upward and apply 1 drop (0.03 mL) to the eye. Make sure the

drop of vaccine spreads over the eye before releasing the bird. It is an important part of

For Official Use Only

successful technique to hold the bird in such a way that the droplet covers the eye surface

and does not run off.

2. Drinking Water

Reconstitution:

Whenever available clean rainwater/tank water containing 2.5 grams of instant skim milk

powder per litre should be used as a diluent for reconstitution.

The vaccine should be prepared immediately before use by tearing the cap off the vial,

removing the rubber stopper and resuspending the virus with prechilled diluent. After

shaking, the reconstituted vaccine is poured into the 3-5 litres of chilled skim milk solution

(2.5 grams of instant skim milk per litre of chilled water).

Administration:

Early morning administration is recommended. At this time there is rapid consumption

of water by the birds in conditions of temperature and light most favourable for effective

vaccination and minimum stress to the flock. Early morning administration also ensures that

the vaccine is reconstituted in cool water.

Drinking water vaccination with Poulvac Laryngo SA2 can be successfully applied through

the lines in sheds with trough or fixed drinkers operating on gravity feed from a holding

tank. It can also be applied directly to drinkers.

For a 3-day period prior to vaccination, the volume of water consumed by the chickens

is calculated over a 2 hour period, preferably in the early morning. This gives a good

indication of the volume of drinking water to be used during vaccination.

NB: During this 3-day period no disinfectants or drugs are to be used through the drinking

system.

a) Medication Tank Method

1. Clean and rinse all drinking troughs thoroughly but do NOT use disinfectants.

2. Empty header tank and fill with sufficient fresh water precalculated to last chickens for 2

hours. Turn off water supply.

3. Add skim milk powder (2.5 grams per litre) and mix thoroughly. This acts as a stabiliser

and protects the live virus in the vaccine.

4. Add the prepared vaccine to the header tank and stir thoroughly to disperse it in the skim

milk/water mixture.

5. Drain the drinking points until the skim milk/vaccine/water mixture appears and fills the

drinkers.

6. Ensure that all birds drink the vaccine supply by driving them gently towards the drinkers.

The vaccine mixture should be consumed within 2 hours.

7. Do not supply water until all the vaccine mixture has been consumed.

b) Direct Dispensing into Drinkers Method

1. Clean and rinse the water trough then turn off the water supply. Do not use disinfectants.

2. Calculate the number of doses required.

3. Prepare the correct volume of chilled water and add skim milk at 2.5 grams per litre.

Dissolve thoroughly. Prepare the correct number of doses as described above (Drinking

Water) and mix thoroughly with the skim milk.

4. Using a clean plastic watering can or bucket, distribute the vaccine mixture evenly to the

water troughs. Keep replenishing the troughs until the total volume in the large container is

used.

5. Make sure the birds drink the vaccine mixture by driving them gently towards the water

troughs. Total consumption of the vaccine should be completed within 2 hours. The birds

must not be allowed access to any other water supply until all the vaccine mixture has been

consumed (as above).

General Directions:

Warning statement:

Research has shown that ILTV vaccine viruses can recombine to potentially form more

virulent strains of ILTV. To minimise the possibility of this happening, ILTV vaccines

For Official Use Only

originating from genetically distinct ILTV strains should not be used concurrently in a

flock or on a site. It is essential that all birds within a flock vaccinated against ILTV each

receive an effective immunising dose to ensure that there are no naive susceptible birds

remaining in the flock. Serology can be used as an indicator of the effectiveness of vaccine

administration.

BACKGROUND:

Infectious Laryngotracheitis (ILT) is an acute respiratory disease produced by an avian

herpesvirus. In chickens ILT produces a tracheitis with gasping and coughing in affected

birds. In severe clinical cases there is a haemorrhagic tracheitis and mortality can be high.

The virus strain used in this vaccine (South Australia SA2 strain) is characterised by low

morbidity and extremely low mortality after tracheal inoculation of susceptible birds. The

vaccine is presented as a living, egg adapted, freeze dried product.

Poulvac Laryngo SA2 is used principally for the preventative vaccination of young stock.

In an acute outbreak of the natural disease, Poulvac Laryngo SA2 may be used in birds

of any age in circumstances where expected losses from the natural infection are judged

by the veterinarian to be greater than production depression in poorly managed flocks

associated with the use of the vaccine.

Withholding

Periods:

Zero (0) days

Trade Advice:

Safety Directions:

First Aid

Instructions:

If poisoning occurs contact a doctor or Poisons Information Centre. Phone Australia

131126

First Aid Warnings:

Additional User

Safety:

Environmental

Statements:

Disposal:

Dispose of vial/container in a designated and appropriately labelled biologicals container.

Please note pack label, instruction leaflet and plastic shell are recyclable.

Storage:

Correct storage and administration of the vaccine is essential.

1. Freeze Dried Vials

The vaccine will remain potent until the expiry date if stored below -5 ° C (frozen). Protect

from light.

2. Reconstituted Vaccine

Once reconstituted the vaccine must be used within 2 hours.

Special precautions should be taken to avoid heat and light damage to the vaccine during

use, especially in open sided iron shedding in summer. If temperatures are expected to be

over 25 ° C small volumes of vaccine should be reconstituted and used quickly. Covered

For Official Use Only

insulated containers containing ice should be used for the movement of vaccine vials from

the main storage area to areas of use around the farm.

Product Name: Poulvac Laryngo SA2

Page: 1 of 5

This revision issued: April, 2013

SAFETY DATA SHEET

Issued by: Pfizer Animal Health Australia Pty Ltd

Phone: 1800 814 883

Poisons Information Centre: 13 1126 from anywhere in Australia, (0800 764 766 in New Zealand)

Section 1 - Identification of The Material and Supplier

Pfizer Animal Health Australia Pty Ltd

38-42 Wharf Road

West Ryde NSW 2114

Tel: 1800 814 883

Fax: (02) 9850 3399

__________________________________________________________

Pfizer Animal Health Australia Pty Ltd

ABN 94 156 476 425

Chemical nature:

Live avian virus freeze dried for reconstitution and use.

Trade Name:

Poulvac Laryngo SA2

APVMA Code:

50573

Product Use:

Vaccine for prevention of infectious laryngotracheitis in poultry.

Creation Date:

April, 2013

This version issued:

April, 2013

and is valid for 5 years from this date.

Section 2 - Hazards Identification

Statement of Hazardous Nature

This product is classified as:

Not classified as hazardous according to the criteria of SWA.

Not a Dangerous Good according to the Australian Dangerous Goods (ADG) Code.

Risk Phrases:

Not Hazardous - No criteria found.

Safety Phrases:

S22, S25, S36. Do not breathe dust. Avoid contact with eyes. Wear suitable protective clothing.

SUSMP Classification:

None allocated.

ADG Classification:

None allocated. Not a Dangerous Good under the ADG Code.

UN Number:

None allocated

GHS Signal word: NONE. Not hazardous.

PREVENTION

P102: Keep out of reach of children.

P235: Keep cool.

RESPONSE

P353: Rinse skin or shower with water.

P301+P330+P331: IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.

P332+P313: If skin irritation occurs: Get medical advice.

P337+P313: If eye irritation persists: Get medical advice.

P370+P378: Not combustible. Use extinguishing media suited to burning materials.

STORAGE

P401: Store at -5°C in the closed original container.

DISPOSAL

P501: Dispose of small quantities and empty containers by wrapping with paper and putting in garbage. For

larger quantities, if recycling or reclaiming is not possible, use a commercial waste disposal service.

E

E

E

m

m

m

e

e

e

r

r

r

g

g

g

e

e

e

n

n

n

c

c

c

y

y

y

O

O

O

v

v

v

e

e

e

r

r

r

v

v

v

i

i

i

e

e

e

w

w

w

Physical Description & colour

: Freeze dried vaccine plug in a glass vial.

Odour:

No data re odour.

Major Health Hazards:

no significant risk factors have been found for this product.

P

P

P

o

o

o

t

t

t

e

e

e

n

n

n

t

t

t

i

i

i

a

a

a

l

l

l

H

H

H

e

e

e

a

a

a

l

l

l

t

t

t

h

h

h

E

E

E

f

f

f

f

f

f

e

e

e

c

c

c

t

t

t

s

s

s

Inhalation:

Short term exposure:

Available data indicates that this product is not harmful. In addition product is unlikely to

cause any discomfort or irritation.

Long Term exposure:

No data for health effects associated with long term inhalation.

Product Name: Poulvac Laryngo SA2

Page: 2 of 5

This revision issued: April, 2013

SAFETY DATA SHEET

Issued by: Pfizer Animal Health Australia Pty Ltd

Phone: 1800 814 883

Poisons Information Centre: 13 1126 from anywhere in Australia, (0800 764 766 in New Zealand)

Skin Contact:

Short term exposure:

Available data indicates that this product is not harmful. It should present no hazards in

normal use. In addition product is unlikely to cause any discomfort in normal use.

Long Term exposure:

No data for health effects associated with long term skin exposure.

Eye Contact:

Short term exposure

: This product may be mildly irritating to eyes, but is unlikely to cause anything more than

mild discomfort which should disappear once product is removed.

Long Term exposure

: No data for health effects associated with long term eye exposure.

Ingestion:

Short term exposure

: Significant oral exposure is considered to be unlikely. However, this product may be

irritating to mucous membranes but is unlikely to cause anything more than transient discomfort.

Long Term exposure

: No data for health effects associated with long term ingestion.

Carcinogen Status:

SWA:

No significant ingredient is classified as carcinogenic by SWA.

NTP:

No significant ingredient is classified as carcinogenic by NTP.

IARC:

No significant ingredient is classified as carcinogenic by IARC.

Section 3 - Composition/Information on Ingredients

Ingredients

CAS No

Conc,%

TWA (mg/m

STEL (mg/m

Infectious laryngotracheitis virus - live

not set

not set

not set

Nystatin

1400-61-9

0.44 unit/dose

not set not set

Gentamicin sulfate

1405-41-0

0.44 µg/dose

not set not set

Other non hazardous ingredients

secret

to 100

not set

not set

This is a commercial product whose exact ratio of components may vary slightly. Minor quantities of other non

hazardous ingredients are also possible.

The SWA TWA exposure value is the average airborne concentration of a particular substance when calculated over a normal 8 hour working day

for a 5 day working week. The STEL (Short Term Exposure Limit) is an exposure value that may be equalled (but should not be exceeded) for no

longer than 15 minutes and should not be repeated more than 4 times per day. There should be at least 60 minutes between successive exposures

at the STEL. The term "peak "is used when the TWA limit, because of the rapid action of the substance, should never be exceeded, even briefly.

Section 4 - First Aid Measures

General Information:

You should call The Poisons Information Centre if you feel that you may have been poisoned, burned or irritated by

this product. The number is 13 1126 from anywhere in Australia (0800 764 766 in New Zealand) and is available at all

times. Have this MSDS with you when you call.

Self Injection: Accidental self injection may lead to an inflammatory response. Medical advice should be sought on

the management of deep injections, particularly those near a joint or associated with bruising. If possible the

application of gentle squeezing pressure with absorbent material (e.g. facial tissues) at the injection site will swab up

unabsorbed vaccine. Strong squeezing of the site should be avoided. The damaged area should be thoroughly

cleansed and a topical antiseptic applied. Check your tetanus immunisation status.

Inhalation:

First aid is not generally required. If in doubt, contact a Poisons Information Centre or a doctor.

Skin Contact:

Gently brush away excess particles. Irritation is unlikely. However, if irritation does occur, flush with

lukewarm, gently flowing water for 5 minutes or until chemical is removed.

Eye Contact:

Quickly and gently brush particles from eyes. No effects expected. If irritation does occur, flush

contaminated eye(s) with lukewarm, gently flowing water for 5 minutes or until the product is removed. Obtain medical

advice if irritation becomes painful or lasts more than a few minutes. Take special care if exposed person is wearing

contact lenses.

Ingestion:

If product is swallowed or gets in mouth, do NOT induce vomiting; wash mouth with water and give some

water to drink. If symptoms develop, or if in doubt contact a Poisons Information Centre or a doctor.

Section 5 - Fire Fighting Measures

Fire and Explosion Hazards

: The major hazard in fires is usually inhalation of heated and toxic or oxygen

deficient (or both), fire gases. There is no risk of an explosion from this product under normal circumstances if it is

involved in a fire.

Extinguishing Media

: Not combustible. Use extinguishing media suited to burning materials.

Fire Fighting

: If a significant quantity of this product is involved in a fire, call the fire brigade.

Product Name: Poulvac Laryngo SA2

Page: 3 of 5

This revision issued: April, 2013

SAFETY DATA SHEET

Issued by: Pfizer Animal Health Australia Pty Ltd

Phone: 1800 814 883

Poisons Information Centre: 13 1126 from anywhere in Australia, (0800 764 766 in New Zealand)

Flash point

:

Does not burn.

Upper Flammability Limit:

Does not burn.

Lower Flammability Limit:

Does not burn.

Autoignition temperature:

Not applicable - does not burn.

Flammability Class:

Does not burn.

Section 6 - Accidental Release Measures

Accidental release

: This product is sold in small packages, and the accidental release from one of these is not

usually a cause for concern. For minor spills, refer to product label for specific instructions. No special protective

clothing is normally necessary because of this product. However it is good practice to wear latex gloves when

handling injectables. In the event of a major spill, prevent spillage from entering drains or water courses and call

emergency services.

Section 7 - Handling and Storage

Handling

: Keep exposure to this product to a minimum, and minimise the quantities kept in work areas. Check

Section 8 of this MSDS for details of personal protective measures, and make sure that those measures are followed.

The measures detailed below under "Storage" should be followed during handling in order to minimise risks to

persons using the product in the workplace. Also, avoid contact or contamination of product with incompatible

materials listed in Section 10.

Storage

: Store packages at -5°C in the closed original container. Make sure that containers of this product are kept

tightly closed. Keep containers dry and away from water. Store in the closed original container in a dry, cool, well-

ventilated area out of direct sunlight. Make sure that the product does not come into contact with substances listed

under "Incompatibilities" in Section 10. Check packaging - there may be further storage instructions on the label.

Section 8 - Exposure Controls and Personal Protection

The following Australian Standards will provide general advice regarding safety clothing and equipment:

Respiratory equipment: AS/NZS 1715, Protective Gloves: AS 2161, Occupational Protective Clothing: AS/NZS 4501

set 2008, Industrial Eye Protection: AS1336 and AS/NZS 1337, Occupational Protective Footwear: AS/NZS2210.

SWA Exposure limits

TWA (mg/m

3

)

STEL (mg/m

3

)

Exposure limits have not been established by SWA for any of the significant ingredients in this product.

No special equipment is usually needed when occasionally handling small quantities. The following instructions are

for bulk handling or where regular exposure in an occupational setting occurs without proper containment systems.

Ventilation:

No special ventilation requirements are normally necessary for this product. However make sure that

the work environment remains clean and that dusts are minimised.

Eye Protection:

Eye protection is not normally necessary when this product is being used. However, if in doubt,

wear suitable protective glasses or goggles.

Skin Protection:

The information at hand indicates that this product is not harmful and that normally no special skin

protection is necessary. However, we suggest that you routinely avoid contact with all chemical products and that you

wear suitable gloves (preferably elbow-length) when skin contact is likely.

Protective Material Types:

There is no specific recommendation for any particular protective material type.

Respirator:

If there is a significant chance that dusts are likely to build up in the area where this product is being

used, we recommend that you use a suitable Dust Mask.

Safety deluge showers should, if practical, be provided near to where this product is being handled commercially.

Section 9 - Physical and Chemical Properties:

Physical Description & colour

Freeze dried vaccine plug in a glass vial.

Odour:

No data re odour.

Boiling Point:

Not applicable.

Freezing/Melting Point:

Decomposes before melting.

Volatiles:

No data.

Vapour Pressure:

Negligible at normal ambient temperatures.

Vapour Density:

Not applicable.

Specific Gravity:

No data.

Water Solubility:

Dispersible.

pH:

No data.

Volatility:

Negligible at normal ambient temperatures.

Odour Threshold:

No data.

Product Name: Poulvac Laryngo SA2

Page: 4 of 5

This revision issued: April, 2013

SAFETY DATA SHEET

Issued by: Pfizer Animal Health Australia Pty Ltd

Phone: 1800 814 883

Poisons Information Centre: 13 1126 from anywhere in Australia, (0800 764 766 in New Zealand)

Evaporation Rate:

Not applicable.

Coeff Oil/water distribution

No data

Viscosity:

Not applicable.

Autoignition temp:

Not applicable - does not burn.

Section 10 - Stability and Reactivity

Reactivity:

This product is unlikely to react or decompose under normal storage conditions. However, if you have

any doubts, contact the supplier for advice on shelf life properties.

Conditions to Avoid:

This product should be kept in a cool place, preferably below 30°C. Keep containers tightly

closed. Containers should be kept dry. Store in the closed original container in a dry, cool, well-ventilated area out of

direct sunlight.

Incompatibilities:

acids, bases, oxidising agents.

Fire Decomposition:

No specific data. Based on composition of proteins and fats, the following might be expected:

Carbon dioxide, and if combustion is incomplete, carbon monoxide and possibly smoke. Nitrogen and its compounds,

and under some circumstances, oxides of nitrogen. Oxides of sulfur (sulfur dioxide is a respiratory hazard) and other

sulfur compounds; also water.

Polymerisation:

This product will not undergo polymerisation reactions.

Section 11 - Toxicological Information

Target Organs:

There is no data to hand indicating any particular target organs.

C

C

C

l

l

l

a

a

a

s

s

s

s

s

s

i

i

i

f

f

f

i

i

i

c

c

c

a

a

a

t

t

t

i

i

i

o

o

o

n

n

n

o

o

o

f

f

f

H

H

H

a

a

a

z

z

z

a

a

a

r

r

r

d

d

d

o

o

o

u

u

u

s

s

s

I

I

I

n

n

n

g

g

g

r

r

r

e

e

e

d

d

d

i

i

i

e

e

e

n

n

n

t

t

t

s

s

s

Ingredient

Risk Phrases

No ingredient mentioned in the HSIS Database is present in this product at hazardous concentrations.

Section 12 - Ecological Information

Insufficient data to be sure of status. Expected to not be an environmental hazard.

Section 13 - Disposal Considerations

Disposal:

Dispose of small quantities and empty containers by wrapping with paper and putting in garbage.

Discarded needles should immediately be placed in a designated and appropriately labelled sharps container. For

larger quantities, if recycling or reclaiming is not possible, use a commercial waste disposal service.

Section 14 - Transport Information

ADG Code:

This product is not classified as a Dangerous Good. No special transport conditions are necessary

unless required by other regulations.

Section 15 - Regulatory Information

AICS:

All of the significant ingredients in this formulation are compliant with NICNAS regulations.

Section 16 - Other Information

This MSDS contains only safety-related information. For other data see product literature.

Acronyms:

ADG Code

Australian Code for the Transport of Dangerous Goods by Road and Rail (7

edition)

AICS

Australian Inventory of Chemical Substances

SWA

Safe Work Australia, formerly ASCC and NOHSC

CAS number

Chemical Abstracts Service Registry Number

Hazchem Code

Emergency action code of numbers and letters that provide information to emergency

services especially firefighters

IARC

International Agency for Research on Cancer

NOS

Not otherwise specified

NTP

National Toxicology Program (USA)

R-Phrase

Risk Phrase

SUSMP

Standard for the Uniform Scheduling of Medicines & Poisons

UN Number

United Nations Number

Contact Points:

Product Name: Poulvac Laryngo SA2

Page: 5 of 5

This revision issued: April, 2013

SAFETY DATA SHEET

Issued by: Pfizer Animal Health Australia Pty Ltd

Phone: 1800 814 883

Poisons Information Centre: 13 1126 from anywhere in Australia, (0800 764 766 in New Zealand)

Pfizer

1800 814 883

Police and Fire Brigade:

Dial 000

If ineffective:

Dial Poisons Information Centre

(

13 1126 from anywhere in Australia)

Please read all labels carefully before using product.

This MSDS is prepared in accord with the SWA document “Preparation of Safety Data Sheets for

Hazardous Chemicals - Code of Practice” (December 2011)

Copyright © Kilford & Kilford Pty Ltd, April, 2013.

http://www.kilford.com.au/

Phone (02)9251 4532

Similar products

Search alerts related to this product

View documents history

Share this information